GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Xinhua Pharmaceutical Co Ltd (HKSE:00719) » Definitions » Construction In Progress

Shandong Xinhua Pharmaceutical Co (HKSE:00719) Construction In Progress : HK$900 Mil (As of Mar. 2024)


View and export this data going back to 1996. Start your Free Trial

What is Shandong Xinhua Pharmaceutical Co Construction In Progress?

Shandong Xinhua Pharmaceutical Co's quarterly construction in progress increased from Sep. 2023 (HK$739 Mil) to Dec. 2023 (HK$799 Mil) and increased from Dec. 2023 (HK$799 Mil) to Mar. 2024 (HK$900 Mil).

Shandong Xinhua Pharmaceutical Co's annual construction in progress declined from Dec. 2021 (HK$689 Mil) to Dec. 2022 (HK$610 Mil) but then increased from Dec. 2022 (HK$610 Mil) to Dec. 2023 (HK$799 Mil).

Shandong Xinhua Pharmaceutical Co Construction In Progress Historical Data

The historical data trend for Shandong Xinhua Pharmaceutical Co's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shandong Xinhua Pharmaceutical Co Construction In Progress Chart

Shandong Xinhua Pharmaceutical Co Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Construction In Progress
Get a 7-Day Free Trial Premium Member Only Premium Member Only 436.35 494.31 689.33 609.61 799.06

Shandong Xinhua Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Construction In Progress Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 707.80 772.17 739.39 799.06 900.02

Shandong Xinhua Pharmaceutical Co Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Shandong Xinhua Pharmaceutical Co (HKSE:00719) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shandong Xinhua Pharmaceutical Co Ltd (HKSE:00719) » Definitions » Construction In Progress
Comparable Companies
SHSE:600812 SZSE:002038 SHSE:600976 SHSE:600195 SHSE:688321 SZSE:000915 SZSE:002424 SZSE:000650 SZSE:002581 SZSE:002219 ZTS XTER:MRK NSE:SUNPHARMA TSE:4502 LSE:HLN XTAE:TEVA XSWX:SDZ VTRS SZSE:000538 NBIX
Traded in Other Exchanges
XIN:Germany 000756:China
Address
No. 1 Lutai Avenue, Hi-tech Industry Development Zone, Zibo City, Shandong, CHN, 255086
Website
http://www.xhzy.com
Shandong Xinhua Pharmaceutical Co Ltd is a pharmaceutical products manufacturer based in China. It operates the business through the following segments: Chemical bulk drugs, Preparations, Chemical intermediates, and other products. The company provides chemical bulk drug products, including metamizole sodium, caffeine, aminopyrine, aspirin, hydrocortisone, pipemidic acid, ibuprofen, and L-dopa, it also dispenses formulation products such as compound liquorice tablets and nimodipine tablets. Its products address disorders related to the central nervous system and the cerebrovascular system with the help of antipyretics and analgesics.

Shandong Xinhua Pharmaceutical Co (HKSE:00719) Headlines

No Headlines